AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$AMGN

Amgen beats estimates but shares dip on biosimilar concerns

Amgen Inc. reported Q3 adjusted EPS of $6.45, beating estimates by $0.69, and revenue of $10.4B, up 8% YoY. Shares fell 1.5% due to biosimilar competition impacting Prolia and XGEVA. Amgen raised 2026 revenue guidance to $38.9B-$39.7B, with growth in UPLIZNA, TEZSPIRE, and Repatha. Free cash flow was $3.7B, down from $4.2B YoY.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AMGN
Bearish
high confidence
Mentioned
$AMGN
Relevance
8/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$AMGNBearishMed
01

Why it matters

The mixed results create a nuanced outlook: short‑term downside pressure versus long‑term growth from pipeline.

02

Market read

Large‑cap biotech earnings with guidance and competitive pressures, relevant for sector and earnings traders.

03

What to watch

Potential upside from upcoming obesity drug MariTide and continued strength in UPLIZNA and TEZSPIRE.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Amgen's Q3 results show strong performance in newer therapies but highlight vulnerability in legacy bone‑health products to biosimilar entrants.

Company-level read

Ticker impact

$AMGNBearishHigh confidence
Context

Amgen reported Q3 earnings beating estimates but shares fell 1.5% after-hours due to biosimilar competition concerns.

Expected impact

likely pressure as investors price in biosimilar competition and modest share dip.

Evidence & confidence

The earnings beat is offset by guidance and product competition, leading to a near‑term sell pressure.

Market effects

Sector

Biosimilar competition may weigh on other biotech firms with similar product lines.

Regional

U.S. biotech sector could see slight pullback.

Global

Limited to investors tracking large‑cap biotech earnings.

Counterpoint

What could challenge this read

The earnings beat and strong growth in newer products could support a rebound if biosimilar impact is overstated.

Key entities

  • company
    Amgen Inc

    Biotech firm reporting Q3 earnings.

Read at source← All news

StoryAmgen posts Q3 2026 earnings, lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

NOV 4
$AMGNMedAI 8/10

What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen reported Q3 sales growth in rare diseases and oncology, with BLINCYTO up 27% and TEPEZZA down 6%. Positive phase III results were announced for small cell lung cancer, eosinophilic esophagitis, and Sjögren's disease. MariTide obesity drug trials are advancing. Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70, with a 6% dividend increase.

finance.yahoo.com7 min
NOV 3
$AMGNHighAI 9/10

AMGN Q3 FY2026 earnings call

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, with 17 products growing double-digit. Non-GAAP operating margin was 47%, and free cash flow reached $3.7B. The company raised full-year 2026 guidance, expecting revenue of $38.9B-$39.7B and EPS of $22.90-$23.70. Key growth drivers include Repatha, EVENITY, TEZSPIRE, and UPLIZNA, with notable increases in rare disease and oncology portfolios.

finance.biggo.com2 min